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Abstract
Background: Prostaglandin E2 (PGE2), the main metabolite of cyclooxygenase (COX), is a well-known anti-fibrotic agent.
Moreover, myofibroblasts expressing a-smooth muscle actin (a-SMA), fibroblast expansion and epithelial-mesenchymal
transition (EMT) are critical to the pathogenesis of idiopathic pulmonary fibrosis (IPF). Our aim was to investigate the
expression of COX-2 and PGE2 in human lung myofibroblasts and establish whether fibroblast-myofibroblast transition
(FMT) and EMT are associated with COX-2 and PGE2 down-regulation.
Methods: Fibroblasts obtained from IPF patients (n = 6) and patients undergoing spontaneous pneumothorax (control,
n = 6) and alveolar epithelial cell line A549 were incubated with TGF-b1 and FMT and EMT markers were evaluated. COX-2
and a-SMA expression, PGE2 secretion and cell proliferation were measured after IL-1b and PGE2 incubation.
Results: Myofibroblasts from both control and IPF fibroblast cultures stimulated with IL-1b showed no COX-2 expression.
IPF fibroblasts showed increased myofibroblast population and reduced COX-2 expression in response to IL-1b. TGF-b1
increased the number of myofibroblasts in a time-dependent manner. In contrast, TGF-b1 induced slight COX-2 expression
at 4 h (without increase in myofibroblasts) and 24 h, but not at 72 h. Both IPF and control cultures incubated with TGF-b1
for 72 h showed diminished COX-2 induction, PGE2 secretion and a-SMA expression after IL-1b addition. The latter
decreased proliferation in fibroblasts but not in myofibroblasts. A549 cells incubated with TGF-b1 for 72 h showed down-
regulated COX-2 expression and low basal PGE2 secretion in response to IL-1b. Immuno-histochemical analysis of IPF lung
tissue showed no COX-2 immuno-reactivity in myofibroblast foci.
Conclusions: Myofibroblasts are associated with COX-2 down-regulation and reduced PGE2 production, which could be
crucial in IPF development and progression.
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Background
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal
interstitial lung disease of uncertain etiology, characterized by the
histopathological pattern of usual interstitial pneumonia. This
fibrotic process involves the loss of lung architecture through
increased epithelial cell apoptosis and abnormal wound healing,
followed by the formation of fibroblast foci and excessive collagen
deposition. In this context, the crucial role of myofibroblasts in
tissue remodeling has been well described [1]. Myofibroblasts
exhibit a contractile and collagen-secretory phenotype, character-
ized by the expression of a-smooth muscle actin (a-SMA). Many
origins have been suggested for these cells [1]. The most important
sources are probably perivascular and peribronchiolar adventitial
fibroblasts, which differentiate into myofibroblasts – a process
known as fibroblast-myofibroblast transition (FMT) – in a pro-
fibrotic environment [1]. Moreover, evidence of the epithelial-
mesenchymal transition (EMT) reveals the importance of epithe-
lial cells as an additional source of myofibroblasts [2]. EMT
involves a transition from epithelial cells to mesenchymal
myofibroblast-like cells that involves a decreased expression of
epithelial markers such as E-cadherin [2].
An imbalance between pro-fibrotic and anti-fibrotic mediators
appears to exist in IPF. Numerous pro-fibrotic factors such as
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transforming growth factor (TGF)-b1 [3] and angiotensin-II [4]
have been reported in IPF. In contrast, few anti-fibrotic mediators
have been identified. Of the latter, prostaglandin E2 (PGE2) is
derived from the metabolism of arachidonic acid by cyclooxygen-
ase enzymes [5]. Experimental models of lung fibrosis show the
pivotal role of this prostaglandin [6,7]. PGE2 enhances epithelial-
mesenchymal wound healing since it improves epithelial cell
survival [8], inhibits fibroblast proliferation [9], collagen I
synthesis [10], cell migration [11] and cell differentiation into
myofibroblasts [12], as well as inducing fibroblast apoptosis [13].
A deficiency of PGE2 synthesis as a result of down-regulation of
cyclooxygenase-2 (COX-2) has been described in IPF [14–16].
Consequently, the inability to induce COX-2 and PGE2 synthesis
has been associated with increased fibroblast proliferation and
alveolar epithelial cell apoptosis [17].
No studies to date have reported any connection between the
myofibroblast phenotype and the lack of PGE2 in IPF. We
hypothesized that the increase in myofibroblast and mesenchymal
myofibroblast-like cell population observed in IPF could be related
to the down-regulation of COX-2 expression and reduced PGE2
synthesis. Therefore, our aim was to study COX-2 regulation and
PGE2 production in myofibroblasts and in FMT and EMT
processes.
Methods
Population
We obtained pulmonary biopsies from patients suffering from
IPF (n = 6). The diagnosis of IPF was established according to the
American Thoracic Society/European Respiratory Society Con-
sensus Statement [18]. None of the IPF patients had received
corticosteroids or other immunosuppressant therapy at the time of
sample collection. As for the control group, we obtained lung
tissue from subjects with no history of pulmonary disease who were
undergoing surgical treatment for spontaneous pneumothorax
(n = 6). No histopathological evidence of disease was found in these
tissue samples. Written informed consent was obtained from all
patients according to institutional guidelines, and the study was
approved by the Ethics Committee of the Hospital Clı´nic,
Barcelona.
Cell Culture and Treatments
Primary fibroblasts were isolated from the lung biopsies, using
previously described methods [19]. Briefly, 1-sq.-mm fragments of
tissue were incubated under sterile conditions in Dulbecco’s
modified Eagle’s media (DMEM) (Lonza, Verviers, Belgium)
supplemented with 10% fetal bovine serum (FBS), 100 IU/ml
penicillin, 100 mg/ml streptomycin (Invitrogen, Carlsbad, Califor-
nia, USA) and 2 mg/ml amphotericin B (Sigma, St Louis, MO,
USA). Cultures were kept in a 5% CO2 humidified atmosphere at
37uC. Fibroblasts were grown to subconfluence and subcultured
by 0.05% trypsin-0.02% EDTA treatment. Fibroblasts were
studied at passage 5 to 6. Culture characterization was performed
by immunofluorescence for vimentin (Invitrogen) and pan-
cytokeratin (C2562, Sigma), as indicated elsewhere [19]. Fibro-
blast cultures stained positive for vimentin and negative for
cytokeratins, demonstrating the absence of epithelial cells in these
cultures.
The A549 human lung adenocarcinoma epithelial cell line
(American Type Culture Collection, Rockville, MD) was cultured
in RPMI 1640 media (Lonza) with 1 mM L-Glutamine (Lonza)
and supplemented as mentioned above.
In all the experiments, the medium was removed when the cell
cultures reached 80% confluence and the cells were incubated in
serum-free medium for 24 h. Three experimental models were
then performed.
In the first set of experiments, fibroblasts were treated with or
without IL-1b (10 ng/ml; R&D systems, Minneapolis, USA), a
well-known inducer of COX-2 expression [15], for 4 and 24 h and
COX-2 and a-SMA expression were measured.
In a second set of experiments, we studied the effect of TGF-b1
(5 ng/ml, R&D systems) in control and IPF cultures for 4, 24 and
72 h. We measured COX-2, a-SMA and collagen Ia1 expression.
With these experiments, we established an in vitro model of FMT
and EMT by incubating fibroblasts and A549 cells, respectively,
with TGF-b1 for 72 h. EMT was also characterized by the
expression of E-cadherin and immunofluorescence.
In a third set of experiments on cells treated with TGF-b1 for
72 h, we studied the effect of IL-1b (10 ng/ml for fibroblasts and
1 ng/ml for A549 cells) and PGE2 (5 ng/ml, Cayman chemicals,
Michigan, USA) for an additional 24 h. The reasons for the use of
a different concentration of IL-1b are firstly based on the literature
[19,20] and secondly based on our experience. We obtained
similar PGE2 levels in both cells using those concentrations,
allowing the comparisons between cell types. Additional TGF-b1
for 4 h and 24 h and the selective COX-2 inhibitor Celecoxib
(10 mM, Sigma) were also tested. In this set of experiments TGF-
b1 was removed at 72 h and fresh culture medium was added with
stimuli. We measured COX-2, COX-1, a-SMA, PGE2 secretion
and proliferation. We also compared these experiments with an
early treatment of TGF- b1 at 4 h. The experiments were carried
out on 6 tissue samples for each group, unless otherwise indicated.
The experiments on A549 cells were performed in quadruplicate,
at the very least.
Western Blot
After treatment, cells plated on 90 cm2-diameter culture dishes
were washed twice with ice-cold phosphate buffer saline (PBS).
Cells were lysated directly with 200 ml of RIPA buffer [TrisHCl
50 mM, NaCl 150 mM (pH 7,4), 1% NP40 Igepal, 1% Triton X-
100, 0.1% SDS and 5 ml/ml of a protease inhibitor cocktail
(Sigma). The lysate was maintained for 20 min on ice and was
then collected and frozen at 280uC. Samples were thawed,
sonicated twice for 15 s in a Sonifier (Branson, Danbury, CT,
USA) and immediately centrifuged at 20,000 g for 10 min at 4uC
for protein measurement. 12.5–30 mg of protein from fibroblasts
and A549 cells were denaturalized in a thermocycler (70uC,
10 min) in loading buffer (NuPAGE LDS sample buffer), loaded
on 7% Tris-Acetate gels and run (125 V, 90 min) in a Novex
XCell II Mini-Cell (Invitrogen, San Diego, CA, USA). The
proteins were then transferred to a nitrocellulose membrane and
non-specific binding sites were blocked using blocking buffer (5%
non-fat dry milk, 0.1% Tween 20 in PBS). Membranes were
incubated overnight at 4uC with 1:1.000 dilution in blocking
buffer of the primary antibodies against COX-2 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), COX-1 (Santa Cruz
Biotechnology), a-SMA (Sigma), E-cadherin (BD Biosciences,
Bedford, MA, USA) or p44/42 MAPK (Erk1/2) (Cell Signalling
Technology) and 1:10.000 dilution for b-actin (Sigma). Blots were
then washed in 0.5% Tween 20 in PBS (T-PBS) and subsequently
incubated for 2 h at room temperature with an appropriate
horseradish peroxidase-labeled secondary antibody diluted 1:3,000
in blocking buffer. After washing with T-PBS, blots were
incubated with an enhanced chemiluminiscent substrate (Super-
signal West Pico Chemiluminescent Substrate, Rockford, IL,
USA). Quantification of protein expression was carried out using a
CCD Camera System LAS 3000 (Fujifilm, Tokyo, Japan) and
densitometry was performed by Image gauge v.4.0 software. For
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the fibroblast Western blots, results were presented as a ratio to the
expression of b-actin. To check for equal loading in A549 cells,
results were expressed as a ratio of band density to total p44/42
MAPK (Erk1/2) since the levels of b-actin underwent changes
after TGF- b1 treatment (data not shown).
Immunofluorescence
Cells grown in 4-well CultureSlidesH were fixed with cold 4%
paraformaldehyde for 15 min and then permeabilized with 0.5%
Triton X-100 for 30 min. Once blocked with 1% bovine serum
albumin-PBS for 1 h, primary antibodies against a-SMA (Sigma,
1:500) or COX-2 (Santa Cruz Biotechnology, 1:500) were added
for 1 h at 37uC. Secondary antibodies or Phalloidin-TRITC
(Sigma) were also incubated for 1 h. Cells were counterstained
with DAPI (1:10.000) and were mounted with ProlongH Gold
antifade reagent (Invitrogen, Molecular Probes).
For double-staining experiments, COX-2 antibody and its
corresponding secondary antibody were first incubated for 45 min
each, and thereafter a-SMA and its secondary antibody were
incubated for another 45 min each. This order was established
empirically in a set of experiments and demonstrated very low
cross-reactivity between antibodies. Phalloidin also showed no
cross-reactivity with COX-2 primary and secondary antibodies
and was incubated together with COX-2 secondary antibody.
Epifluorescence microscopy (Leica Microsystems, Germany) was
used to analyze preparations at 6200 or 6400 magnification.
Positive cells for a-SMA and COX-2 were counted in 12 random
fields.
Immunohistochemistry
Histological sections were obtained from paraffin-embedded
biopsies of control (n = 5) and IPF patients (n = 5). Paraffin was
removed and sections were heated at 80uC for 40 min in citrate
buffer (0.01 M, pH 6) for the antigen retrieval process. Then,
samples were blocked in PBS, 0.05% v/v Triton X-100, 3% goat
serum (Sigma) for 30 min at room temperature. Primary
antibodies against COX-2 (Santa Cruz Biotechnology) and a-
SMA (Sigma) diluted 1:1000 in blocking solution were incubated
overnight at 4uC. The next steps were performed using
EnVisionTM Detection Systems Peroxidase/DAB, Rabbit/Mouse
kit (Dako, Denmark), according to the manufacturer’s instructions.
Nuclei were contrasted with Gill I Hematoxylin for 1 min.
Sections were mounted using GlycergelH Mounting Medium
(Dako).
Analysis of DNA Replication (Click-iTH)
A commercial kit was used, based on the incorporation of EdU
(5-ethynyl-29-deoxyuridine), a modified nucleoside that is incor-
porated during DNA synthesis (Click-iTH, Invitrogen). After
treatment, cells grown in 90-sq.-cm dishes were incubated with
10 mM EdU for 2 h before being harvested them for flow
cytometry measurements (Click-iTH EdU Alexa FluorH 488 Flow
Cytometry Assay Kit, Invitrogen). The next steps were performed
in accordance with the manufacturer’s instructions. The technique
was validated with a set of experiments incubating cells with
increasing concentrations of serum. Results were presented as
percentage of cells incorporating the modified nucleoside EdU.
Negative control was also measured to establish positive criteria.
Collagen Expression
Total RNA was isolated with the RNeasy mini kit (Qiagen,
Mississauga, ON, CA) according to the instructions of the
manufacturer. One mg of RNA was reverse-transcribed into
cDNA with the High Capacity cDNA Reverse Transcriptase kit
with RNase Inhibitor (Applied Biosystems, Life Technologies,
Wellesley, CA) using random primers, optimized RT Buffer,
dNTP’s and MultiScribeTM MuLV reverse transcriptase. cDNA
was subjected to amplification by real-time PCR (7900 HT Fast
Real-Time PCR System, Applied Biosystems) using TaqManH
Gene Expression Assays (Applied Biosystems) for collagen type I,
alpha 1 (COLIA1; Assay Id: Hs00164004_m1) and RNA
polymerase II, polypeptide A (RPII; Assay Id: Hs00172187_m1)
as a constitutive endogenous gene. Data were calculated using the
DDCt method and the results expressed as fold-change related to
control samples at time 0 h.
Sircol Collagen Assay
Total soluble collagen in cell culture supernatants was
quantified using the Sircol collagen assay (Biocolor, Belfast, UK).
Briefly, 500 ml of fibroblast culture supernatant were collected and
concentrated overnight using the kit’s concentration reagent. 1 ml
of Sirius red dye was added and incubated with gentle rotation for
30 min at room temperature. After centrifugation at 12,000 g for
10 min, the collagen-dye pellet was washed with 750 mL of cold
Acid-Salt Wash Reagent and centrifuged again. The pellet was re-
dissolved with 250 mL of 0.5 M NaOH, and absorbance at
540 nm was measured by microplate ELISA reader. The results
are presented as total mg Collagen secreted/mg total protein
content.
PGE2 Assay
PGE2 Assay was performed in cell culture medium using
Prostaglandin E2 EIA Kit (Cayman chemicals). Supernatants were
filtered through 0.22 mm filter (BD Biosciences) and stored at
280uC. The measurement was performed according to the
manufacturer’s instructions. Results are presented as total pg
PGE2 secreted/mg total protein content.
Statistical Data Analysis
All statistical analyses were performed with SPSS 14.0 (SPSS,
Chicago, IL USA). Data are expressed as median and 25th to 75th
percentile. Immunofluorescence cell count results are presented in
tables as mean values6 SD. The non-parametric statistical Mann-
Whitney U-test was used for control and IPF group comparisons
and the Wilcoxon test was used for paired comparisons.
Parametric statistical analyses for A549 cells experiments were
performed with ANOVA followed by Dunnett’s multiple com-
parison post hoc tests. Differences were considered to be
significant if p-values were below 0.05.
Results
Expression of COX-2 and a-SMA in Control and IPF
Fibroblasts
IPF cultures showed increased population of myofibroblasts (a-
SMA positive cells) basally and reduced population of COX-2
positive cells in response to IL-1b (10 ng/ml for 24 h) compared
with control cells, as observed by immunofluorescence (Table 1).
As described elsewhere [15,16], western blot showed a diminished
induction of COX-2 expression in response to IL-1b stimulation in
IPF fibroblasts compared to control cells (Fig. S1). A significant
decrease in a-SMA positive cells was found after 24 h of IL-1b
treatment in both groups. Interestingly, a-SMA positive cells
showed little or no expression of COX-2 in response to IL-1b
(Table 1, Fig. 1). This finding demonstrates that spontaneous
myofibroblasts present in culture are characterized by diminished
COX-2 expression in response to IL-1b.
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Induction of Fibroblast-myofibroblast Transition by TGF-
b1
In order to induce myofibroblasts in our cultures, we used TGF-
b1 (5 ng/ml). This treatment provoked a significant increase in
myofibroblasts (a-SMA-positive cells) in a time-dependent man-
ner, reaching statistically significant values at 24 and 72 h in both
cultures (Fig. 2A). Interestingly, the TGF-b1 treatment induced a
similar amount of myofibroblasts in the control and IPF cell
cultures at both points. Consequently, the differences between
control and IPF in the number of myofibroblasts in non-treated
cells were lost. Representative images of TGF-b1 induction of
FMT are presented (Fig. 2B).
In the control fibroblasts, TGF-b1 stimulated COX-2 expres-
sion slightly at 4 h and more markedly at 24 h but no COX-2
expression was observed at 72 h. In IPF treated fibroblasts, no
COX-2 expression was observed after TGF-b1 treatment (Fig. 2C).
Consequently, in control fibroblasts, we observed COX-2
expression at 4 h induced by TGF-b1 without any statistical
changes in the number of myofibroblasts and the opposite
situation in long-term treatment with TGF-b1 (72 h), which is
characterized by a myofibroblast-enriched population with no
expression of COX-2. RT-PCR showed a marked up-regulation of
collagen Ia1 synthesis in fibroblasts after TGF-b1 treatment, a
characteristic feature of the myofibroblast phenotype. This
increase was significantly higher in IPF samples treated with
TGF-b1 compared to control treated samples (Fig. 2D).
We also performed Sircol assay in order to measure the secreted
collagen in IPF and Control fibroblast cultures under the same
experimental conditions. The results are presented as total mg
Collagen secreted/mg total protein content. Although the same
pattern found in collagen mRNA expression was observed, no
significant differences were found between control and IPF
fibroblasts. (Control 0 h: 0.03560.02; IPF 0 h: 0.04360.01;
Control 72 h: 0.07860.02*; IPF 72 h: 0.08460.03*; Con-
trol+TGF-b1 72 h: 0.12260.04*{; IPF+TGF-b1 72 h:
0.13560.03**{{). (*p,0.05 and ** p,0.01 vs. 0 h; { p,0.05
and {{ p,0.01 vs. 72 h without treatment). N = 6 each. We found
Sircol analysis insufficiently sensitive to find these differences in
our samples.
Myofibroblast Phenotype from FMT Results in Down-
regulation of COX-2 Expression
We studied COX-2 and a-SMA expression in the myofibro-
blast-enriched cultures obtained as described in Figure 2. Both
groups presented a marked increase in a-SMA expression when
treated with TGF-b1 (Fig. 3A). The TGF-b1-treated cells showed
a dramatic decrease in COX-2 expression in response to IL-1b
(Fig. 3A, B).
Consequently, an increase in a-SMA positive cells was
associated with a decrease in COX-2 positive cells induced by
IL-1b (Fig. 3C). Cells positive for COX-2 were almost absent in
the TGF-b1-treated cultures. The cell counting of co-immunoflu-
orescence is summarized in Table 2. As expected, an extremely
low number of a-SMA positive cells were also positive for COX-2
after IL-1b treatment.
COX-1 expression increased after TGF-b1 treatment only in
IPF fibroblasts (Fig. 3D), whereas it remained unmodified by IL-
1b in both groups (densitometry not shown).
Immunofluorescence revealed that cells positive for COX-2
presented a thin fibroblast-like shape and a-SMA negativity.
Figure 1. Co-immunofluorescence of COX-2 (red) and a-SMA (green) of a representative control fibroblast culture. In basal conditions
(left), it shows no COX-2 expression and isolated a-SMA-positive cells, and after IL-1b treatment for 24 h (right), it shows high COX-2 expression and a
lack of COX-2 immunoreactivity in a-SMA-positive cells. Nuclei were stained with DAPI (blue). (Original magnification X200).
doi:10.1371/journal.pone.0065445.g001
Table 1. Quantification of immunofluorescence of COX-2, a-
SMA and COX-2+ a-SMA.
Treatment (24 h) Determinations Control Group IPF Group
None COX-2 ND ND
a-SMA 2.861.6% 9.463.7%**
IL-1b (10 ng/ml) COX-2 48.05611.09% 31.765.7%*
a-SMA 1.662.7% { 5.162.8%*{
COX-2 & a-SMA 0.0160.10% 0.1760.11%
Quantification of immunofluorescence of COX-2, a-SMA and COX-2+ a-SMA.
Control and IPF fibroblasts were incubated for 24 h in the presence or absence
of IL-1b (10 ng/ml). Results are presented as mean 6 SD of the percentage of
total cells. ND, not detected.
*P,0.05 and **P,0.01 compared to control group,
{P,0.05 compared to the respective untreated cells.
doi:10.1371/journal.pone.0065445.t001
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Figure 2. Induction of fibroblast-myofibroblast transition (FMT) in control and IPF fibroblasts by TGF-b1 incubation. (A)
Quantification of a-SMA positive cells (myofibroblasts) by immunofluorescence. Results are presented as percentage of total cells. (B) Representative
immunofluorescence showing the effect of 5 ng/ml TGF-b1 for 72 h in control fibroblasts. The expression of a-SMA is shown in green and the nuclei
were stained with DAPI (blue) (Original magnification X200). (C) Representative Western blot of COX-2 and b-actin in two fibroblast cultures obtained
from both control and IPF patients in response to TGF-b1 treatment at 4, 24 and 72 h. Densitometric analysis of COX-2 expressed as a ratio versus b-
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Consequently, myofibroblasts (a-SMA positive cells) showed no
positive staining for COX-2 (Fig. 3E, Table 2).
Re-stimulation of myofibroblasts with TGF-b1 for additional 4
and 24 h produced no COX-2 expression, as expected (Fig. S3).
Induction of Epithelial-mesenchymal Transition by TGF-
b1 Results in Down-regulation of COX-2 Expression
We studied EMT by treating A549 cells with TGF-b1 (5 ng/ml,
72 h), as described above. Epithelial-specific marker E-cadherin
dramatically decreased in treated A549 cells (Fig. 4A). Immuno-
fluorescence using phalloidin (F-actin marker) showed a strong red
staining in A549 cells incubated with TGF-b1, revealing
cytoskeleton remodeling and a morphological change into a
myofibroblast-like phenotype (Fig. 4B). RT-PCR showed a
marked up-regulation of collagen Ia1 synthesis in A549 cells after
TGF-b1 treatment (Fig. 4C). Weak expression of a-SMA and no
expression of COX-1 in A549 were found, either basally or after
stimulation with TGF-b1 (results not shown).
Unlike fibroblasts, A549 cells expressed COX-2 in the absence
of IL-1b stimulation (Fig. 4D). Interestingly, TGF-b1 treatment for
72 h decreased this basal COX-2 expression. We then observed an
increase in COX-2 expression in response to IL-1b (1 ng/ml),
which was reduced in TGF-b1-treated cells (Fig. 4D). This
inhibition can be clearly observed by immunofluorescence
(Fig. 4E).
Myofibroblast Phenotype from FMT and EMT Implies a
Decrease in PGE2 Synthesis
We examined PGE2 levels in culture supernatants of control,
IPF fibroblasts (Fig. 5A) and A549 cells (Fig. 5B) treated with
TGF-b1. IL-1b incubation increased PGE2 secretion in fibroblasts
and A549 cells. This effect was diminished in TGF-b1 pretreated
cells (Fig. 5A, B). The results correlated with COX-2 Western blot
analysis and immunofluorescence. Therefore, a myofibroblast-like
phenotype is associated with a notable decrease in PGE2 secretion.
COX-2 Down-regulation of Myofibroblast-like Phenotype
Alters Cell Proliferation
We studied the role of COX-2 and PGE2 in myofibroblast-
enriched culture proliferation by the Click-iTH technique.
Fibroblasts and A549 cells were incubated with IL-1b (10 ng/ml
and 1 ng/ml respectively), PGE2 (5 ng/ml) and the selective
COX-2 inhibitor Celecoxib (10 mM) for 24 h.
In fibroblast control cells, IL-1b treatment provoked a
significant decrease in proliferation (Fig. 6A). This decrease
appears to be mediated by COX-2 since PGE2 completely
abrogated cell proliferation and the addition of Celecoxib reversed
the IL-1b effect. IPF fibroblasts presented a diminished prolifer-
ation compared with control fibroblasts, but similar effects were
observed after incubation with IL-1b, PGE2 and Celecoxib.
Moreover, TGF-b1 treatment induced a decrease in control
fibroblast proliferation but no differences were observed in IPF
fibroblast cultures. Interestingly, the inhibitory effect on prolifer-
ation associated with IL-1b exposure was annulled in TGF-b1
treated cells (Fig. 6A).
In A549 cells, incubation with IL-1b significantly reduced cell
proliferation in both TGF-b1-treated and non-TGF-b1-treated
cells (Fig. 6B). This effect seems to be independent of COX-2 and
PGE2 since Celecoxib was not able to restore control levels and
PGE2 itself had no effect on cell proliferation. Furthermore, we
observed that TGF-b1 treatment significantly increased cell
proliferation.
Myofibroblast Foci in IPF Lungs are Characterized by the
Presence of a-SMA and Absence of COX-2
The localization of a-SMA and COX-2 was examined by
immunohistochemistry in IPF and control lung tissue. Epithelial
cells from control tissue were slightly stained for COX-2 (Fig. 7A)
and staining of a-SMA was present in airway smooth muscle cells
(Fig. 7B). Moreover, in IPF tissue a-SMA was strongly localized in
fibroblast/myofibroblast foci (Black arrows, Fig. 7D). Interestingly,
metaplastic epithelial cells presented strong COX-2 staining but
fibroblast/myofibroblast foci showed no COX-2 expression
(White arrows, Fig. 7C). Immuno-histochemical staining for a-
SMA and COX-2 was negative in histological slides incubated
without the primary antibody.
Discussion
IPF is characterized by increased expression of TGF-b1,
increased myofibroblast numbers and reduced production of
PGE2 resulting from a limited induction of COX-2. We postulated
that the three findings are somehow related. Consequently, we
hypothesized that myofibroblasts are characterized by an impaired
COX-2 expression and reduced PGE2 secretion.
We first confirmed previous studies reporting that IPF
fibroblasts cultures are characterized by reduced COX-2 expres-
sion [15] but increased a-SMA [21,22] compared with control
fibroblast cultures. Since COX-2 was not detected at baseline,
stimulation with IL-1b was performed. This first confirmation
suggests that our cell lines behave as published by other groups.
We must point out that the use of lung fibroblasts obtained from
patients with spontaneous pneumothorax as subrogate of ‘‘nor-
mal’’ (control) lung has some limitations. Although histological
analysis of control tissue was normal in our patients, previous
studies have reported that fibroblasts obtained from surgical
resections during pleurodesis for spontaneous pneumothorax, may
proceed from areas with pathological abnormalities, including
inflammatory and fibrotic reactions [23]. To the best of our
knowledge, however, there are not other better options to obtain
samples from healthy or minimally affected lung tissue.
We secondly analyzed the relationship between COX-2
expression and the myofibroblast phenotype using an immuno-
fluorescence technique. Interestingly, myofibroblasts stained neg-
ative for COX-2 after IL-1b stimulation, suggesting that the
myofibroblast phenotype is characterized by an down-regulated
COX-2 expression. Cells expressing COX-2 were thinner, smaller
and sharper than myofibroblasts. IL-1b treatment also decreased
the number of myofibroblasts, thereby confirming this cytokine as
a potent inhibitor of FMT, as has been described [12]. We could
not find any morphological difference between fibroblasts
expressing COX-2 and those not expressing it.
All in all, these findings suggest that myofibroblast transforma-
tion eventually results in the down-regulation of COX-2. The
presence of more myofibroblast in fibroblast cultures and in the
lung in IPF may account for the reported low induction of COX-2
in IPF tissues. However, the small difference between the
percentages of myofibroblasts in IPF and control lung fibroblast
cultures – together with the observation that COX-2-expressing
actin is also shown. N = 6 Control cells. N = 4–6 IPF cells. (D) Collagen Ia1 mRNA measured by real-time PCR with or without TGF-b1 treatment (5 ng/
ml) for 72 h in control and IPF fibroblasts. *P,0.05 compared to respective untreated cells, #P,0.05 and ##P,0.01 compared to control group.
doi:10.1371/journal.pone.0065445.g002
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Figure 3. Effect of IL-1b stimulation on a myofibroblast-enriched population. (A) Protein levels in control and IPF fibroblasts of COX-2, COX-
1, a-SMA and b-actin at 72 h with or without TGF-b1 treatment (5 ng/ml), and at subsequent 24 h in the presence or absence of IL-1b (10 ng/ml),
measured by Western blot. (B) Densitometric analysis of COX-2 expressed as a ratio versus b-actin. (C) Quantification of COX-2 positive cells by
Cyclooxygenase-2 Impairment in Lung Myofibroblasts
PLOS ONE | www.plosone.org 7 June 2013 | Volume 8 | Issue 6 | e65445
fibroblasts were apparently indistinguishable from non-COX-2-
expressing fibroblasts – suggests that the mechanisms involved in
the down-regulation of COX-2 may also be present in IPF
fibroblasts (a-SMA negative cells).
To gain insight into the relationship between myofibroblast
phenotype and COX-2 regulation, the myofibroblast numbers
were increased by inducing the transition of fibroblast into
myofibroblast with TGF-b1. As previously described, we observed
that TGF-b1 myofibroblast induction was time and dose-
dependent [12] and was accompanied by a strong increase in
collagen Ia1 expression [1], with greater expression of collagen
Ia1 in IPF cultures than in control cultures. In contrast, the Sircol
method was not sensitive enough to find any significant differences
between control and IPF cells in our samples. The percentage of
myofibroblasts markedly increased in cultures, to the same extent
as in the IPF and control fibroblasts.
Previous reports have demonstrated that TGF-b1 increases
COX-2 expression and PGE2 synthesis in fibroblasts over short
periods (2–24 h) [24–26]. These reports agree with our results,
since we observed increased COX-2 induced by TGF-b1 at 4 and
24 h in control fibroblasts. The number of myofibroblasts
remained low at those time points. At longer times (72 h), the
high amount of myofibroblasts resulted in reduced COX-2
expression. Moreover, after we treated control cells with IL-1b
from that time point for additional 4 or 24 h, COX-2 expression
was reduced dramatically. In contrast, we could not observe
induction of COX-2 expression in IPF cultures after TGF-b1
treatment, even after short periods. We performed experiments at
4 h with and without TGF-b1 and with and without IL-1b and we
observed that, together, both treatments enhanced COX-2
expression, as described elsewhere (see Fig. S2) [27]. We cannot
rule out therefore that FMT is characterized by an initial phase
with a slight up-regulation of COX-2. Another possibility is that
incubation with TGF-b1 produces an increase in COX-2
expression, independent of FMT. Future experiments (e.g. the
use of other FMT inducers) would help us to clarify this matter
and to accurately determine the stage at which myofibroblasts
finally down-regulate COX-2.
Consequently, the number of cells expressing COX-2 after
stimulation with IL-1b after 72 h of TGF-b1 decreases in parallel
with the increase in the number of fibroblasts transformed into
myofibroblasts. In addition, re-incubation with TGF-b1 for an
additional 4 and 24 h only induced COX-2 if the culture was not
enriched with myofibroblasts (see Fig. S3), discarding a possible
artifact of rapid expression/degradation of the enzyme. However,
in those long-term studies, the level of COX-2 induction in
response to IL-1b was not as homogeneous as in short-term studies
and variability was found, mainly in control cells and not related to
technique employed. Interestingly, patients with the highest levels
of COX-2 after IL-1b stimulation in long-term studies showed the
lowest numbers of a-SMA positive cells before IL-1b treatment
and vice versa. The origin of the variability in terms of a-SMA or
in terms of COX-2 expression is unknown but both parameters
are clearly related as we have shown. Since TGF-b1 increases
dramatically a-SMA positive cells in all cell lines studied, reduced
COX-2 expression after TGF-b1 treatment is consistent in all the
patients studied.
With long-term studies we confirmed our previous observations
linking down-regulation of COX-2 with the myofibroblast
phenotype. We also investigated the secretion of PGE2 in
myofibroblast-enriched cultures. PGE2 secretion induced by IL-
1b in TGF-b1-treated fibroblasts was strongly reduced in both the
control and IPF patients, as a result of the inhibition of COX-2
caused by long-term exposure to TGF-b1.
immunofluorescence. Results are presented as percentage of total cells. (D) COX-1/b-actin ratio at 72 h in the presence or absence of TGF-b1 (5 ng/
ml). *P,0.05 compared to untreated cells, #P,0.05 compared to IL-1b treated cells, {P,0.05 and `P,0.01 compared to control group in the same
conditions. (E) Representative co-immunofluorescence image of COX-2 (red) and a-SMA (green) of a myofibroblast-enriched culture obtained from
control fibroblasts stimulated with IL-1b for 24 h. Nuclei were stained with DAPI (blue). Note that myofibroblasts do not express COX-2 in response to
IL-1b and the different shape of the COX-2 positive cells (Original magnification X400).
doi:10.1371/journal.pone.0065445.g003
Table 2. Quantification of immunofluorescence of COX-2, a-SMA and COX-2+ a-SMA.
Treatment Determinations Control Group IPF Group
None (72 h) None (24 h) COX-2 ND ND
a-SMA 2.969% 9.262.9% **
IL-1b (10 ng/ml, 24 h) COX-2 41.2616.3% { 26.765.2% *{
a-SMA 1.762.5% { 6.0564.1% *{
COX-2 & a-SMA 0.0260.07% 0.1460.09%
TGF-b1 (5 ng/ml, 72 h) None (24 h) COX-2 ND ND
a-SMA 82.365.3% ` 79.968.9% `
IL-1b (10 ng/ml, 24 h) COX-2 9.968.5% ` 7.465.3% `
a-SMA 70.7611.9% `1 72.4611.04% `1
COX-2 & a-SMA 0.460.5% 0.360.07%
Quantification of immunofluorescence of COX-2, a-SMA and COX-2+ a-SMA. Control and IPF fibroblasts were incubated for 72 h in the presence or absence of TGF-b1,
followed by further incubation in the absence or presence of IL-1b (10 ng/ml) for 24 h. Results are presented as mean 6 SD of the percentage of total cells. ND, not
detected,
*P,0.05 and ** P,0.01 compared to control group in the same conditions,
{P,0.05 compared to the respective untreated cells,
`P,0.05 compared to non-treated TGF-b1 cells.
1P,0.05 compared to percentage of a-SMA in TGF-b1 treated cells in the absence of IL-1b.
doi:10.1371/journal.pone.0065445.t002
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The incubation of TGF-b1-treated cells with IL-1b provoked a
reduction in a-SMA positive cells, suggesting that IL-1b not only
inhibits myofibroblast cell transition but also promotes the
disappearance of myofibroblasts in culture. Interestingly, COX-1
expression only increased significantly after TGF-b1 treatment in
fibroblasts obtained from IPF patients. Since the reduction of
COX-2 in IPF fibroblast cultures is notable, we are tempted to
speculate that these cells may respond to TGF-b1 treatment by
increasing COX-1 expression to maintain basal COX metabolism.
We studied A549 cells, which are widely used as a model of
EMT [28,29]. However, the tumour origin of the cell line limits
the extrapolation of the results to primary epithelial pulmonary
cells. These cells are useful for studying COX-2 expression since
they do not express COX-1 and show high basal COX-2
expression [30]. In A549 cells, TGF-b1 treatment decreased basal
COX-2 expression and provoked a diminished COX-2 induction
after IL-1b stimulation. Accordingly, PGE2 levels paralleled
COX-2 expression. Therefore, the EMT process leading the
myofibroblast-like phenotype could also contribute to the down-
regulation of COX-2 and PGE2 observed in IPF.
We also examined the interrelationship between TGF-b1, IL-
1b, COX-2 and PGE2 in proliferation once the cells were
transformed into myofibroblasts. Interestingly, treatment with IL-
1b decreased proliferation in control fibroblasts. This effect may
be mediated by COX-2 activation, since the selective COX-2
inhibitor Celecoxib completely restored cell proliferation. In
contrast, the anti-proliferative effect of IL-1b was lost in
myofibroblasts from both the control and the IPF patients. The
lack of any effect of IL-1b on myofibroblasts appears to be the
result of impaired COX-2 induction. Consequently, the exogenous
addition of the COX-2 metabolite PGE2 decreased cell prolifer-
ation not only in fibroblasts but also in myofibroblasts. Our
findings agree with reports of the anti-proliferative effects of PGE2
in various cell types [9].
The incubation of A549 cells with TGF-b1 may inhibit
epithelial cell proliferation [31]. We studied the proliferation of
A549s after their transformation into myofibroblast-like phenotype
by TGF-b1 treatment. In these conditions, we found increased cell
proliferation in cells treated with TGF-b1 compared to untreated
cells. The treatment of A549 cells with IL-1b provoked a
remarkable decrease in proliferation compared with untreated
cells. This effect does not seem to be mediated by COX-2 and
PGE2, since the COX-2 inhibitor Celecoxib did not restore
proliferation and PGE2 treatment had no inhibitory effect on cell
proliferation. Our results suggest that PGE2 may modulate cell
proliferation specifically in FMT but not in EMT, and they point
to PGE2 as a potential therapeutic treatment for IPF, largely on
account of its targeting of myofibroblasts. A recent report has
demonstrated that PGE2 deficiency in IPF results in increased
alveolar epithelial cell apoptosis and reduced sensitivity of
fibroblasts to apoptosis [17]. Consequently, PGE2 may also
regulate apoptosis differentially in fibroblasts and epithelial cells.
We also studied histological slides of control and IPF human
lungs. In line with previous reports [32], we observed a slight basal
COX-2 expression in epithelial cells and a-SMA staining in airway
smooth muscle cells from control lungs. Little or no COX-2
staining was observed, however, in the fibroblast and myofibro-
blast foci of IPF patients. Moreover, we observed, in keeping with
Lappi-Blanco [33], increased COX-2 staining in epithelial
metaplastic tissue in IPF. Therefore, cells that maintain the
epithelial phenotype have high COX-2 expression while fibro-
blast/myofibroblast areas do not express the enzyme. Clearly, our
Figure 4. Induction of epithelial-mesenchymal transition (EMT) in A549 cells by TGF-b1 incubation and effect of IL-1b in
transformed cells. Effect of 5 ng/ml TGF-b1 for 72 h in A549 cell culture. (A) Representative Western blot of four replicates of E-cadherin and ERK 1/
2. (B) Representative immunofluorescence showing the expression of F-actin (stained with phalloidin, red) and bright field (Original magnification
X400). (C) Collagen Ia1 mRNA measured by real-time PCR. Effect of IL-1b for 24 h (1 ng/ml) in A549 cells after incubation with 5 ng/ml TGF-b1 (72 h).
(D) Representative Western blot and densitometric analysis of COX-2 expression versus ERK 1/2. *P,0.05 compared to untreated cells, #P,0.01
compared to IL-1b-treated cells. (E) Immunofluorescence of COX-2 (green) and F-actin (stained with phalloidin, red) in cells cultured in absence
(upper) or presence (lower) of TGF-b1. In both images, cells were stimulated with IL-1b (1 ng/ml). Nuclei were stained with DAPI (blue). Note the
almost complete absence of COX-2 staining in TGF-b1-treated cells (original magnification X400).
doi:10.1371/journal.pone.0065445.g004
Figure 5. Measurement of PGE2 secretion after FMT or EMT
induction. Control and IPF fibroblasts (A) and A549 cells (B) were
incubated for 72 h in the presence or absence of TGF-b1 (5 ng/ml),
followed by treatment in the presence or absence of IL-1b (10 ng/ml or
1 ng/ml, respectively) for 24 h. Supernatant was then collected and
total PGE2 was measured using Prostaglandin E2 EIA Kit (Cayman).
Results are expressed as PGE2 secreted/mg total protein content.
*P,0.05 compared to untreated cells, {P,0.05 and #P,0.01 compared
to IL-1b-treated cells.
doi:10.1371/journal.pone.0065445.g005
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Figure 6. Cell proliferation measured by the analysis of DNA replication. For this purpose, control and IPF fibroblasts (A) and A549 cells (B)
were incubated for 72 h in the presence or absence of TGF-b1 (5 ng/ml), followed by treatment in the presence or absence of IL-1b (10 ng/ml or
1 ng/ml, respectively), PGE2 (5 ng/ml) and the selective COX-2 inhibitor Celecoxib (10 mM). Cell proliferation was then analyzed by measuring the
incorporation of the modified nucleoside EdU into the DNA using the Click-iTH commercial kit. Cells were incubated with 10 mM EdU for 2 h before
being harvested for flow cytometry measurements. Results are expressed as the percentage of EdU positive cells. *P,0.05 and **P,0.01 compared to
respective untreated cells, #P,0.05 compared to control group in the same conditions, {P,0.05 compared to non-treated TGF-b1 cells in the same
conditions.
doi:10.1371/journal.pone.0065445.g006
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model of A549 cells does not mirror metaplastic epithelial cells as
the latter present diminished COX-2 expression after treatment
with TGF-b1. They may represent cells undergoing EMT in the
fibrotic foci, or elsewhere in the interstitial space.
The mechanisms of COX-2 inhibition in the myofibroblast
phenotype remain unknown. Recent findings suggest that defec-
tive histone acetylation in the COX-2 promoter may be
responsible for the diminished COX-2 gene transcription observed
in IPF fibroblasts [34]. Since PGE2 has shown potent anti-fibrotic
properties in several studies [9–13], the effect of an altered
secretion of PGE2 could easily be linked to the development of
fibrotic processes. Further studies are needed to clarify whether the
abrogation of COX-2 in the myofibroblasts of IPF is irreversible.
Conclusions
The myofibroblast phenotype is associated with a down-
regulation of COX-2 and, consequently, a reduced production
of its main metabolite PGE2. These events could be crucial in IPF
development and progression. Finally, our results suggest that
targeting COX-2 and/or PGE2 could be a potential therapy for
IPF.
Supporting Information
Figure S1 Expression of COX-2, COX-1 and a-SMA in
control (n= 5) and IPF (n=5) fibroblasts basally and
induced by IL-1b (10 ng/ml) for 4 and 24 h. (A) Represen-
tative image of a Western blot and (B) densitometric analysis of
COX-2 expressed as ratio versus b-actin expression. *P,0.05
compared to respective untreated cells, #P,0.05 compared to
control group in same conditions.
(TIF)
Figure S2 Protein levels of COX-2, COX-1, a-SMA and
b-actin in control and IPF fibroblasts stimulated for 4 h.
Cells were incubated in the presence or absence of IL-1b (10 ng/
ml) and/or TGF-b1 (5 ng/ml) for 4 h. (A) Representative image of
a Western blot. (B) Densitometric analysis of COX-2 expressed as
ratio versus b-actin expression. * P,0.05 compared to respective
untreated cells, { P,0.05 compared to IL-1b treated cells in the
same group.
(TIF)
Figure S3 Absence of COX-2 expression in control cells
stimulated for 72 h with TGF-b1 and further incubation
for 4 or 24 h with renewed TGF-b1. Cells were incubated in
the presence or absence of TGF-b1 (5 ng/ml) for 72 h and for
Figure 7. Immuno-histochemical detection of COX-2 and a-SMA in healthy lung tissue (A–B) and in idiopathic pulmonary fibrosis
tissue (C–D). Immuno-localizations of COX-2 (A–C) and a-SMA (B–D) are shown. The image shows slight basal expression of COX-2 and isolated a-
SMA staining related to a-SMA-positive cells in control tissue. In contrast, increased a-SMA staining (black arrows) and absence of COX-2 expression
(white arrows) are observed in fibroblastic foci. Metaplastic epithelium presents widespread expression of COX-2 (Original magnification X200).
doi:10.1371/journal.pone.0065445.g007
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additional 4 or 24 h of fresh TGF-b1 (5 ng/ml). Representative
Western blot of a control fibroblast culture.
(TIF)
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